IP Library Patent Application 12552468
Patent Application
App. No. 12/552,468

Concentrating White Blood Cells for DNA Extraction from a Leukodepleted Blood Sample

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/552,468
Abstract

Reagents and a method for the pre-concentration of WBCs from leukodepleted blood segment samples are described. The reagent comprises: a lytic reagent, for example, saponin in phosphate buffered saline(PBS), wherein the amount of saponin is in the range of from about 1% to about 10% percent (w/w). The method comprises: contacting a specific volume the leukoreduced blood segment sample with a specific volume of the lytic regent; mixing the two so as to selectively lyse RBCs in the leukoreduced whole blood segment sample; subjecting the mixture to centrifugation, so as to separate the mixture into a WBC rich phase and a lysed-RBC phase; discarding the supernatant containing the lysed RBC phase; and resuspending the WBC rich phase in a specific volume of PBS.

Claims (18)

1 . A method for extracting genomic DNA from leukoreduced blood samples, the method comprising:

contacting a specific volume the leukoreduced blood sample with a specific volume of a lytic reagent capable of lysing red blood cells;

mixing the two so as to selectively lyse red blood cells in the leukoreduced blood sample;

subjecting the lysed mixture to centrifugation, so as to separate the mixture into a white blood cell rich sediment and a supernatant rich in lysed-red blood cells;

discarding the supernatant;

resuspending the white blood cell rich phase in a specific volume of aqueous buffer; and

extracting DNA from the buffered white blood cell suspension.

2 . The method of claim 1 , wherein the lytic reagent comprises saponin dissolved in phosphate buffered saline.

3 . The method of claim 2 wherein the amount of saponin in the lytic reagent is from about 1% to about 10% percent (w/w).

4 . The method of claim 2 wherein the lytic reagent further includes alkali and the pH is near neutral.

5 . The method of claim 1 , wherein the volume of the leukoreduced blood sample is about 0.2 ml to about 2 ml.

6 . The method of claim 5 , wherein the volume of the lytic reagent is about 40 μl to about 80 μl.

7 . The method of claim 1 , wherein the buffer is selected from the group consisting of hydrogenated phosphates of sodium and potassium.

8 . The method of claim 1 , wherein the centrifugation is done at about 300×g to 2000×g and for about 2 to 6 minutes.

9 . The method of claim 1 wherein the centrifugation is at 2000×g for 3 minutes.

10 . The method of claim 1 , wherein the volume of buffer used for WBC resuspension is from about 50 μl to about 500 μl.

11 . The method of claim 1 wherein the resuspension of the white blood cell rich phase in phosphate buffered saline is by vortexing.

12 . The method of any of claims 1 to 3 further comprising the step of isolating genomic DNA from the white blood cell rich phase.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS Recorded Jul 2, 2020
From: CITIBANK, N.A.
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; IMMUCOR GTI DIAGNOSTICS, INC.; SIRONA GENONICS, INC.
Reel/Frame 053121/0935 →
PATENT SECURITY AGREEMENT Recorded Aug 19, 2011
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026778/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2011
From: BANERJEE, SUKANTA
To: BIOARRAY SOLUTIONS, LTD.
Reel/Frame 026571/0673 →